Treatment response in CML - Chronic Myeloid Leukemia
|
Types of responses: Hematologic response (HR) Complete hematologic response (CHR) Major cytogenetic response (MCR or MCyR) Complete cytogenetic response (CCR or CCyR) Major molecular response (MMR) Complete molecular response (CMR) |
Reduction of white cells Normal count of white cells 1 - 35% Ph+ cells No Ph+ cells BCR-ABL IS ≤ 0.10% no BCR-ABL detectible |
SITES
Molecular response: a measure of treatment success in Philadelphia chromosome-positive
Chronic Myeloid Leukemia (Ph+ CML) by CMLadvocates
Responses by The National CML Society
Current Monitoring for CML: Goals and Principles by Md Anderson Cancer Center – Dr Jorge Cortes
Molecular response: a measure of treatment success in Philadelphia chromosome-positive
Chronic Myeloid Leukemia (Ph+ CML) by CMLadvocates
Responses by The National CML Society
Current Monitoring for CML: Goals and Principles by Md Anderson Cancer Center – Dr Jorge Cortes
VIDEOS
CML molecular monitoring: Practical advice
April 15, 2016, ImedexCME
Resistant Chronic Myeloid Leukemia
June 19, 2015, Leukemia & Lymphoma Society
CML molecular monitoring: Practical advice
April 15, 2016, ImedexCME
Resistant Chronic Myeloid Leukemia
June 19, 2015, Leukemia & Lymphoma Society
ARTICLES
BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase
July 21, 2015, Leukemia
Molecular response in CML: where is the bar? | Blood Journal
2014, Blood Journal
Monitoring the Response to Tyrosine Kinase Inhibitor (TKI) Treatment in Chronic Myeloid Leukemia (CML)
2014, NCBI
2013 European LeukemiaNet Recommendations for Management of Chronic Myeloid Leukemia
2013, BloodRef
Major Molecular Response in CML Patients Treated with Tyrosine Kinase Inhibitors: The Paradigm for Monitoring Targeted Cancer Therapy
June 21, 2010, The Oncologist
Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia
May 20, 2008, Blood Journal
BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase
July 21, 2015, Leukemia
Molecular response in CML: where is the bar? | Blood Journal
2014, Blood Journal
Monitoring the Response to Tyrosine Kinase Inhibitor (TKI) Treatment in Chronic Myeloid Leukemia (CML)
2014, NCBI
2013 European LeukemiaNet Recommendations for Management of Chronic Myeloid Leukemia
2013, BloodRef
Major Molecular Response in CML Patients Treated with Tyrosine Kinase Inhibitors: The Paradigm for Monitoring Targeted Cancer Therapy
June 21, 2010, The Oncologist
Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia
May 20, 2008, Blood Journal
